title: TiO2-based Mitoxantrone Imprinted Poly (Methacrylic acid-co-polycaprolctone diacrylate) Nanoparticles as a Drug Delivery System.
abstract: Light delivery in photodynamic therapy is a challenging issue in deep cancer treatment. To solve this problem, photosensitizers are conjugated to X-ray luminescent nanoparticles. When the complexes are stimulated by X-rays during radiotherapy, the nanoparticles generate light and activate the photosensitizers.
  
  
  
  Core-shell molecularly imprinted polymers (MIPs) were prepared against mitoxantrone (MX) in which TiO2 nanoparticles were applied as a core, diacrylated polycaprolctone as a biodegradable cross-linker and methacrylic acid (MAA) or 4-vinylpyridin (4-VP) as the functional monomer. TiO2 was selected as a scintillator, MX as a photosensitizer and MIP as a drug delivery system in order to evaluate the possibility of using photodynamic therapy (PDT) during radiotherapy in the next studies. Binding properties of polymers and drug release profile were studied and the optimized MIP was characterized by SEM, TEM, EDS, FT-IR and XRD. Also, cytotoxicity and free radical production were also studied in vitro.
  
  
  
  Data indicated that MAA-based MIP had superior binding properties compared to its non-imprinted polymer (NIP) and higher imprinting factor value than MIP-4VP. Drug release experiments indicated higher MX released amount from MAA-based MIP than the other polymers. MAA-based MIP was selected as an optimized carrier for MX delivery system. According to the results, the size of MX-MIP@TiO2 was reported to be less than 75 nm. The free radical production and cytotoxicity of nanoparticles were also evaluated in vitro.
  
  
  
  The results of the present work proposed the possibility of applying MIP layer as a drug delivery system around TiO2 nanoparticles.
authors.affiliation: Department of Medical Physics, Mashhad University of Medical Sciences, Mashhad, Iran.
authors.forename: Maryam
authors.initials: M
authors.lastname: Bakhshizadeh
authors.affiliation: Medical Physics Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
authors.forename: Ameneh
authors.initials: A
authors.lastname: Sazgarnia
authors.affiliation: Biotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
authors.forename: Mahmoud
authors.initials: M
authors.lastname: Seifi
authors.affiliation: Biotechnology Research Center, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
authors.forename: Farzin
authors.initials: F
authors.lastname: Hadizadeh
authors.affiliation: Department of Nanotechnology, Research Institute of Food Science and Technology, Mashhad, Iran.
authors.forename: Ghadir
authors.initials: G
authors.lastname: Rajabzadeh
authors.affiliation: Pharmaceutical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
authors.forename: Seyed Ahmad
authors.initials: SA
authors.lastname: Mohajeri
mesh_terms: D000179:Acrylates / Q000008:administration & dosage / Q000737:chemistry / Q000378:metabolism; D045744:Cell Line, Tumor; D016503:Drug Delivery Systems; D005609:Free Radicals / Q000037:antagonists & inhibitors / Q000378:metabolism; D006801:Humans; D008689:Methacrylates / Q000008:administration & dosage* / Q000737:chemistry / Q000378:metabolism; D008942:Mitoxantrone / Q000008:administration & dosage* / Q000737:chemistry / Q000378:metabolism; D053758:Nanoparticles / Q000008:administration & dosage* / Q000737:chemistry / Q000378:metabolism; D011091:Polyesters / Q000008:administration & dosage* / Q000737:chemistry / Q000378:metabolism; D014025:Titanium / Q000008:administration & dosage* / Q000737:chemistry / Q000378:metabolism; D014961:X-Ray Diffraction
chemical_list: D000179:Acrylates; D005609:Free Radicals; D008689:Methacrylates; D011091:Polyesters; C009495:titanium dioxide; C008384:methacrylic acid; C016240:polycaprolactone; D008942:Mitoxantrone; D014025:Titanium; C036658:acrylic acid
keywords: Drug delivery system; TiO2; mitoxantrone; molecularly imprinted polymer; nanoparticle; polymers and drug release